New Insights from EMBRACE Phase 2a Study on Emapalumab in Treating Sepsis Recent results from the EMBRACE Phase 2a study show promising outcomes for emapalumab in treating interferon-gamma-driven sepsis.

New Insights from EMBRACE Phase 2a Study on Emapalumab in Treating Sepsis #Sweden #Stockholm #sepsis #Gamifant #emapalumab

US Hemophagocytic Lymphohistiocytosis Market Set for Exceptional Growth at 24.5% CAGR from 2025 to 2034 The Hemophagocytic Lymphohistiocytosis (HLH) market in the US forecasts a remarkable CAGR of 24.5% from 2025 to 2034, driven by innovative therapies and rising incidences.

US Hemophagocytic Lymphohistiocytosis Market Set for Exceptional Growth at 24.5% CAGR from 2025 to 2034 #United_States #Las_Vegas #Gamifant #Hemophagocytic_Lymphohistiocytosis #Plonmarlimab

Sobi Accelerates Development of Gamifant® for Managing Interferon-Gamma-Driven Sepsis Based on EMBRACE Findings Sobi is moving forward with Gamifant® for interferon-gamma-driven sepsis, following encouraging results from the Phase 2a EMBRACE study. This article explores the implications.

Sobi Accelerates Development of Gamifant® for Managing Interferon-Gamma-Driven Sepsis Based on EMBRACE Findings #Sweden #Stockholm #sepsis #Gamifant #Interferon-gamma

Sobi's Gamifant® (emapalumab) Shows Promise in Sepsis Treatment Based on EMBRACE Study Results Sobi® announces significant findings from the EMBRACE study indicating Gamifant’s potential in treating interferon-gamma-driven sepsis, promising pathways for clinical development.

Sobi's Gamifant® (emapalumab) Shows Promise in Sepsis Treatment Based on EMBRACE Study Results #Sweden #Stockholm #Sobi #sepsis #Gamifant

Sobi Adjusts 2025 Outlook: Strong Q3 Performance and Key Developments Ahead Swedish Orphan Biovitrum (Sobi) witnesses impressive growth in Q3 2025. Adjusted financial projections indicate a positive trajectory for the year.

Sobi Adjusts 2025 Outlook: Strong Q3 Performance and Key Developments Ahead #Sweden #Stockholm #Sobi #Doptelet #Gamifant

Gamifant® Receives FDA Approval as a Breakthrough Treatment for Macrophage Activation Syndrome The FDA has approved Gamifant® as a pioneering treatment for macrophage activation syndrome in Still's disease, benefiting both children and adults.

Gamifant® Receives FDA Approval as a Breakthrough Treatment for Macrophage Activation Syndrome #USA #FDA_Approval #Stockholm #Sobi #Gamifant

Sobi's Upcoming Presentation of Clinical Data at EULAR 2025 Conference Sobi will unveil new findings at EULAR 2025 in Barcelona, showcasing advancements in treatments for rare rheumatological diseases, including Gamifant and Vonjo.

Sobi's Upcoming Presentation of Clinical Data at EULAR 2025 Conference #Sweden #Stockholm #Sobi #Gamifant #VEXAS

Sobi's New Research Collaboration for Gamifant® in Sepsis Aims to Revolutionize Treatment Options Sobi has unveiled a significant research collaboration to advance Gamifant® (emapalumab) for treating a severe form of sepsis, to be discussed at ISICEM.

Sobi's New Research Collaboration for Gamifant® in Sepsis Aims to Revolutionize Treatment Options #Sweden #Stockholm #Sobi #Gamifant #emapalumab

U.S. FDA Prioritizes Review of Sobi's Gamifant® for Serious Complications in Still's Disease Sobi's Gamifant® is under priority review by the FDA for treatment in serious cases of hemophagocytic lymphohistiocytosis and macrophage activation syndrome.

U.S. FDA Prioritizes Review of Sobi's Gamifant® for Serious Complications in Still's Disease #United_States #Stockholm #Sobi #Gamifant #HLH